Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study

Archive ouverte

Mekinian, Arsène | Grignano, Eric | Braun, Thorsten | Decaux, Olivier | Liozon, Eric | Costedoat-Chalumeau, Nathalie | Kahn, Jean-Emmanuel | Hamidou, Mohammed | Park, Sophie | Puéchal, Xavier | Toussirot, Eric | Falgarone, Géraldine | Launay, David | Morel, Nathalie | Trouiller, Sébastien | Mathian, Alexis | Gombert, Bruno | Schoindre, Yoland | Lioger, Bertrand | Wazieres, Benoit De | Amoura, Zahir | Buchdaul, Anne-Laure | Georgin-Lavialle, Sophie | Dion, Jérémie | Madaule, Serge | Raffray, Loïc | Cathebras, Pascal | Piette, Jean Charles | Rose, Christian | Ziza, Jean Marc | Lortholary, Olivier | Montestruc, Francois | Omouri, Mohammed | Denis, Guillaume | Rossignol, Julien | Nimubona, Stanislas | Adès, Lionel | Gardin, Claude | Fenaux, Pierre | Fain, Olivier

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Objective. We describe myelodysplastic syndrome (MDS)–associated systemic inflammatory and autoimmune diseases (SIADs), their treatments and outcomes and the impact of SIADs on overall survival in a French multicentre retrospective study. Methods. In this study, 123 patients with MDS and SIADs were analysed. Results. Mean age was 70 years (s.d. 13) and the male:female ratio was 2. The SIADs were systemic vasculitis in 39 (32%) cases, CTD in 31 (25%) cases, inflammatory arthritis in 28 (23%) cases, a neutrophilic disorder in 12 (10%) cases and unclassified in 13 cases (11%). The SIADs fulfilled the usual classification criteria in 75 (66%) cases, while complete criteria were not reached in 21 (19%) cases. A significant association was shown between chronic myelomonocytic leukaemia (CMML) and systemic vasculitis (P = 0.0024). One hundred and eighteen (96%) SIAD patients were treated (91% with steroids), with an 83% response to first-line treatment, including 80% for steroids alone. A second-line treatment for SIADs was required for steroid dependence or relapse in 48% of cases. The effect of MDS treatment on SIADs could be assessed in 11 patients treated with azacytidine and SIAD response was achieved in 9/11 (80%) and 6/11 (55%) patients at 3 and 6 months, respectively. Compared with 665 MDS/CMML patients without SIADs, MDS/CMML patients with SIADs were younger (P \textless 0.01), male (P = 0.03), less often had refractory anaemia with ring sideroblasts (P \textless 0.01), more often had a poor karyotype (16% vs 11%, P = 0.04) and less frequently belonged to low and intermediate-1 International Prognostic Scoring System categories, but no survival difference was seen between patients with MDS-associated SIADs and without SIADs (P = 0.5). Conclusion. The spectrum of SIADs associated to MDS is heterogeneous, steroid sensitive, but often steroid dependent

Consulter en ligne

Suggestions

Du même auteur

Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases

Archive ouverte | Mekinian, Arsène | CCSD

International audience. We describe the characteristics and outcome of inflammatory arthritis in patients with myelodysplastic syndrome (MDS) in a French multicenter retrospective study. Twenty-two patients with MDS...

Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review

Archive ouverte | Grignano, Eric | CCSD

International audience. We wanted to describe the characteristics, treatment and outcome of autoimmune and inflammatory diseases (SAIDs) associated with chronic myelomonocytic leukemia (CMML), and conducted a French...

Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Archive ouverte | Fraison, Jean-Baptiste | CCSD

International audience. This retrospective study describes efficacy of Azacitidine on autoimmune disorders (AID) associated with MDS/CMML in 22 patients. Response of AID to Azacitidine was observed in 19 patients (8...

Chargement des enrichissements...